
An investigational therapy targeting tau protein has shown continued benefits in slowing clinical decline in patients with early Alzheimer’s disease, according to data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference.
The therapy, known as diranersen, is an antisense oligonucleotide designed to reduce both intracellular and extracellular tau. Results from the open-label extension of the phase II CELIA trial showed that diranersen slowed decline across measures of cognition, function, and disease progression over 96 weeks.
Slowing Decline Across Multiple Measures
Other measurements of cognition and function also improved from 76 to 96 weeks. Lawren VandeVrede, MD, PhD, of the University of California San Francisco, noted that the increasing separation between 18 months and 2 years was particularly remarkable.
Safety Profile and Study Design
Safety findings through week 96 were consistent with the placebo-controlled period. The most frequent adverse events included procedural pain, post-lumbar puncture syndrome, headache, and confusional state. Most confusional state events were mild or moderate and resolved within 7 days.
The CELIA trial enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. It evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period.
While all doses slowed cognitive decline, the lowest dose performed best, missing the primary endpoint of demonstrating a clear dose response. The ongoing open-label extension continues to evaluate the therapy’s long-term safety and clinical benefit.
Implications for Alzheimer’s Treatment
The trial provided the first evidence from a randomized study that lowering tau may slow cognitive decline. Laura Nisenbaum, PhD, of the Alzheimer’s Drug Discovery Foundation, noted that the therapy’s ability to lower tau without affecting amyloid makes it a promising candidate for combination treatments.
New data from the placebo-controlled period showed favorable memory, orientation, and executive function scores in the 60-mg group at 18 months. Biomarker analyses confirmed that diranersen reduced tau PET signals and lowered soluble tau biomarker levels.